Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 2/2010

01-03-2010 | Letter to the Editor

Reply to the letter by Bedognetti et al. “Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era”

Authors: Shigeru Kusumoto, Yasuhito Tanaka

Published in: International Journal of Hematology | Issue 2/2010

Login to get access

Excerpt

Reactivation of hepatitis B virus (HBV) has been reported not only in hepatitis B surface antigen (HBsAg)-positive patients undergoing systemic chemotherapy, but also in a proportion of HBsAg-negative patients with antibody to HBsAg (anti-HBs) and/or antibody to hepatitis B core antigen (anti-HBc) [1‐4]. Recently, rituximab-plus-steroid combination chemotherapy (R-CHOP, etc.) has been identified as a risk factor for HBV reactivation in HBsAg-negative patients with malignant lymphoma [2]. …
Literature
1.
Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344:68–9.CrossRefPubMed
2.
Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.CrossRefPubMed
3.
Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–11.CrossRefPubMed
4.
Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.CrossRefPubMed
5.
Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1–20.PubMed
6.
Tanaka E, Umemura T. History and prevention of de novo hepatitis B virus-related hapatitis in Japan and the world. Clin J Gastroenterol. 2008;1:83–6.CrossRef
7.
8.
Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307.CrossRefPubMed
9.
Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol. 2005;42:813–9.CrossRefPubMed
Metadata
Title
Reply to the letter by Bedognetti et al. “Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era”
Authors
Shigeru Kusumoto
Yasuhito Tanaka
Publication date
01-03-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0523-y

Other articles of this Issue 2/2010

International Journal of Hematology 2/2010 Go to the issue

Letter to the Editor

Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era

Guideline

Guidelines for safety management of granulocyte transfusion in Japan

Letter to the Editor

Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer

Letter to the Editor

Natural pregnancy and delivery after unrelated bone marrow transplantation using fludarabine-based regimen in a Fanconi anemia patient

Original Article

Significance of immature platelet fraction and CD41-positive cells at birth in early onset neonatal thrombocytopenia

Letter to the Editor

Non-cirrhotic extrahepatic portal vein thrombosis: a 6-year long case history
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits